{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:14:18Z","timestamp":1792512858009,"version":"4.5.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Telitacicept, a B lymphocyte stimulator\/A proliferation-inducing ligand dual-target fusion protein, mainly used for IgA nephropathy and systemic lupus erythematosus. We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, Telitacicept represents a promising additional treatment option for patients suffering from IgA vasculitis (IgAV).<\/jats:p>","DOI":"10.3389\/fimmu.2025.1564242","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:39:08Z","timestamp":1746077948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuang-xi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-kang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-liang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-bin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2014.4.1.42","article-title":"Age of onset as a risk factor of renal involvement in Henoch-Sch\u00f6nlein purpura","volume":"4","author":"Ghrahani","year":"2014","journal-title":"Asia Pacific Allergy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.07.021","article-title":"Clinical characteristics and treatment patterns of children and adults with igA nephropathy or igA vasculitis: findings from the cureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatol (Oxford England)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with igA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000540326","article-title":"Efficacy and safety of telitacicept in igA nephropathy: A retrospective, multicenter study","volume":"149","author":"Liu","year":"2024","journal-title":"Nephron"},{"key":"B6","doi-asserted-by":"publisher","first-page":"sfae285","DOI":"10.1093\/ckj\/sfae285","article-title":"Efficacy and safety of Telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study","volume":"17","author":"Wang","year":"2024","journal-title":"Clin Kidney J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating gd-igA1 and igA-containing immune complexes in igA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0667","article-title":"Effects of corticosteroid on Henoch-Sch\u00f6nlein purpura: a systematic review","volume":"120","author":"Weiss","year":"2007","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD005128","DOI":"10.1002\/14651858.CD005128.pub3","article-title":"Interventions for preventing and treating kidney disease in Henoch-Sch\u00f6nlein Purpura (HSP)","volume":"2015","author":"Hahn","year":"201","journal-title":"Cochrane Database Systematic Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.2010.150","article-title":"Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein Purpura","volume":"78","author":"Pillebout","year":"2010","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100534","DOI":"10.1016\/j.xkme.2022.100534","article-title":"Mycophenolate mofetil for severe igA vasculitis nephropathy in children: an observational study","volume":"4","author":"Samsonov","year":"2022","journal-title":"Kidney Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000341914","article-title":"The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Sch\u00f6nlein purpura nephritis","volume":"36","author":"Ren","year":"2012","journal-title":"Am J Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"sfae115","DOI":"10.1093\/ckj\/sfae115","article-title":"The efficacy and safety of tacrolimus in treating refractory IgA vasculitis nephritis: a single-center retrospective study on 16 cases","volume":"17","author":"Gan","year":"2024","journal-title":"Clin Kidney J"},{"key":"B14","article-title":"Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis","volume":"83","author":"O\u2019Donoghue","year":"1992","journal-title":"Clin Sci (London England: 1979)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.40339","article-title":"Brief report: rituximab for the treatment of adult-onset igA vasculitis (Henoch-sch\u00f6nlein)","volume":"70","author":"Maritati","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken N.J.)"},{"key":"B16","first-page":"195","article-title":"Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis","author":"Fenoglio","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with igA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:39:09Z","timestamp":1746077949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1564242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2025.1564242"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1564242","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"1564242"}}